论文部分内容阅读
目的:观察芪扶正胶囊在卵巢癌化疗并发症预防中的效果。方法:纳入2014年1月至2015年3月我院收治的卵巢癌患者73例,按随机数字表法分为观察组36例和对照组37例,对照组患者术后给予常规化疗药物进行治疗,观察组患者在对照组化疗基础上加用贞芪扶正胶囊治疗,记录并分析治疗后两组患者癌抗原125、人附睾分泌蛋白4、腹水深度、卡式评分(KPS评分)、肿瘤病人生活质量评分(QOL评分)、血红蛋白(HGB)、血小板(PLT)和白细胞(WBC)、谷丙转氨酶(ALT)和总胆红素(TBIL)水平变化、治疗疗效以及不良反应发生率。结果:观察组化疗后癌抗原125水平为(56.4±10.3)IU/ml,明显低于对照组(83.7±15.7)IU/ml;观察组化疗后人附睾分泌蛋白4为(162.9±60.1)pmol/L,明显低于对照组(284.6±80.5)pmol/L;观察组化疗后腹水深度为(2.13±0.42)cm,明显低于对照组(3.26±0.72)cm;4观察组化疗后KPS评分和QOL评分分别为(88.62±5.68、44.18±4.45)分,均明显高于对照组(80.67±5.16、36.91±4.22)分;5治疗后观察组化疗后并发症比例为16.67%,明显低于对照组37.84%;6治疗后观察组HGB下降、PLT下降、WBC下降比例均明显低于对照组。结论:贞芪扶正胶囊在卵巢癌化疗中可提高癌症病人的生活质量并且降低化疗过程中的不良反应发生率。
Objective: To observe the effect of Qifuzheng Capsule on the prevention of chemotherapy complications in ovarian cancer. Methods: Totally 73 ovarian cancer patients admitted to our hospital from January 2014 to March 2015 were divided into observation group (36 cases) and control group (37 cases) according to random number table method. Patients in the control group were treated with conventional chemotherapeutic drugs . The patients in the observation group were treated with Zhenqi Fuzheng Capsule on the basis of the chemotherapy in the control group. The levels of cancer antigen 125, human epididymal secreted protein 4, ascites depth, card score (KPS score), tumor patient’s life QOL score, HGB, PLT and WBC, ALT and TBIL, the curative effect and incidence of adverse reactions were also analyzed. Results: The level of cancer antigen 125 in observation group after chemotherapy was 56.4 ± 10.3 IU / ml, which was significantly lower than that in control group (83.7 ± 15.7 IU / ml). The secretion of protein 4 in epididymis was (162.9 ± 60.1) pmol / L, which was significantly lower than that of the control group (284.6 ± 80.5 pmol / L). The depth of ascites in the observation group after chemotherapy was (2.13 ± 0.42) cm, which was significantly lower than that in the control group (3.26 ± 0.72) cm.4 The KPS score And QOL score were (88.62 ± 5.68, 44.18 ± 4.45) points, respectively, which were significantly higher than that of the control group (80.67 ± 5.16,36.91 ± 4.22) points; 5 after treatment, the complication rate of the observation group was 16.67% 37.84% in the control group; 6 after treatment, HGB decreased, PLT decreased, WBC decreased significantly lower than the control group. Conclusion: Zhenqi Fuzheng Capsule can improve the quality of life of cancer patients and reduce the incidence of adverse reactions during chemotherapy in ovarian cancer chemotherapy.